Recently, the Shenzhen Enterprise Innovation Promotion Conference, organized by the Shenzhen Industry Federation, was grandly held. At the conference, the scientific and technological innovation achievements shortlisted for the 24th "Shenzhen Enterprise Innovation Record" were announced and commended.
With the fat-reduction efficacy supported by in-depth mechanistic research and substantial scientific data, Xbiome's fat-reduction patent "Chinese Strain" XA-1416 has been approved and officially recorded.Shenzhen Enterprise Innovation (China) RecordIn addition, Xbiome was selected as a "Shenzhen Enterprise Innovation Record - Independent Innovation Benchmark Enterprise" and included in the "2025 Guangdong-Hong Kong-Macao Greater Bay Area Enterprise Innovation Power List - Future Creators Star List." Dr. Tan Yan, Co-founder and CEO of Xbiome, was honored with the titles of "Shenzhen Enterprise Innovation Record - Outstanding Contribution Figure for Innovation" and "2025 Guangdong-Hong Kong-Macao Greater Bay Area Enterprise Innovation Power List - Innovative Distinguished Figure."
XA-1416: The Scientific Research Story of "Chinese Microbiota"
Included in the Shenzhen Enterprise Innovation (China) Record"Xbiome's Development of Patent Strain XA-1416 for Fat Reduction"The project is one of the core R&D achievements of Xbiome's deep cultivation in "China-produced bacteria," and XA-1416 is also a star strain discovered by Xbiome using its pharmaceutical-grade AI+BT technology platform.
XA-1416 has been officially approved for a national invention patent. According to the patent application documents, this strain canFour Major Scientific Mechanisms Achieve "Intelligent Fat Reduction"The strain can reduce the efficiency of fat absorption in the intestines and accelerate fat excretion; it can delay gastric emptying, increase satiety, and safely regulate blood glucose levels without side effects; it can reduce the Firmicutes/Bacteroidetes ratio and restore a healthy microbial balance; it can decrease lipid droplet accumulation in fat cells and reduce the proportion of visceral fat and white fat.
Notably, XA-1416 is a "Chinese-origin strain" and "independently researched strain" isolated from the gut of healthy individuals in the Chinese population. The Xbiome scientific team, relying on their self-established Chinese Gut Biobank (XGB), utilized cutting-edge technologies such as high-throughput sequencing and metagenomic analysis to precisely screen and identify the XA-1416 strain. Compared to overseas strains, this strain is more compatible with the intestinal environment of the Chinese population, offering enhanced adaptability and safety.Upon its debut, XA-1416 was featured in special reports by national-level media such as Xinhua News Agency and Outlook Oriental Magazine, and was hailed as a representative of "China's microbiome."
To further investigate the clinical value of XA-1416, inShenzhen Science and Technology Major Special ProjectWith the support of, Xbiome andSchool of Public Health, Sun Yat-sen University (Shenzhen)Collaborate to conduct a randomized, double-blind, placebo-controlled clinical study on XA-1416, using a pharmaceutical-grade RCT protocol to verify the fat-reduction effects and mechanisms of XA-1416 in humans. Currently, the project'sVolunteer Recruitment is Currently Underway, research experts invite citizens and friends in Shenzhen to sign up and participate, to jointly experience safe, healthy, and effortless fat reduction and weight loss.
Xbiome Wins Four Major Awards for Probiotics Research and Innovation
The "Shenzhen Enterprise Innovation Record" review event, personally promoted and guided by important pioneers and leaders of China's industrial economy, is organized by the Shenzhen Industry Federation and jointly carried out by 13 government departments and dozens of industry associations. It aims to promote independent innovation among Shenzhen enterprises and enhance productivity levels. By 2025, it will have been held for the 24th session. This year’s winning projects come from full-track technology companies in biotechnology, medical devices, software, and information services.
This honor award garnered by Xbiome,Covering two major authoritative systems: the Shenzhen Enterprise Innovation Record and the Guangdong-Hong Kong-Macao Greater Bay Area Enterprise Innovation Power List,Demonstrates the company's comprehensive strength and leading position in the innovative field of gut microbiome.
For years, Xbiome has heavily invested in the construction of AI+BT technology platforms and fundamental scientific research on gut microbiota, providing strong support for industrial innovation. Through cutting-edge technical methods such as whole-genome analysis, metabolite prediction, metabolite identification, and in vivo and in vitro functional validation, Xbiome's scientific team efficiently selects innovative functional strains for mechanism research, function validation, animal and human trials, patent application and protection, ultimately applying them to probiotic use cases.
Currently, Xbiome has applied for dozens of patents for its self-developed strains, and so far, 9 of them have been officially authorized by the state. The patented strains developed by the company for applications such as weight management, bone health, gut health, immune enhancement, and cancer treatment have all become highly sought-after star strains in fields like probiotics, health and wellness, food and beverages, and biopharmaceuticals.
With strong scientific research capabilities and a rich matrix of patented strains, Xbiome has collaborated withMead Johnson (China), Fonterra, WonderLab, Chayan YueseLeading companies both in China and abroad have reached comprehensive business cooperation in joint R&D, strain licensing, and raw material contract manufacturing, serving the global food and probiotics enterprises.Provide Scientifically Evidence-Based Probiotic Solutions。
Xbiome will adhere to the development philosophy of "innovation-driven and quality first," based on the R&D achievements of the XA-1416 strain, continue to deeply cultivate gut microbiome research. More innovative achievements of "Chinese bacteria" will benefit a wide range of consumers and patients, using the gut microbiome to protect the intestinal health of the Chinese people, contributing to the high-quality development of the biomedicine and large health industry.
Note: The above content does not involve product efficacy promotion. It is solely based on publicly available patent application materials and is intended for the scientific introduction of raw material strains.
-End-